ImmVira (亦诺微) Pre-IPO: Prospectus Update Suggests Stronger Bladder Data but a Higher Competitive Bar
ImmVira has filed an updated HKEX Chapter 18A application proof. Its value depends on MVR-T3011 in BCG-unresponsive bladder cancer, where approved...
144 Views
Immvira Bioscience (IBS HK): Synthetic Expert Call Transcript (18 Jul 2026)
Immvira Bioscience’s immediate survival hinges entirely on the success of its newly refiled Hong Kong IPO as of July 16, 2026. The company’s...
116 Views
IPO Databook: Immvira Bioscience (HK) - Jul 2026
Immvira Bioscience Inc. is a clinical-stage biotechnology company focused on novel oncolytic immunotherapies and engineered exosome therapies,...
111 Views
Primer: Immvira Bioscience (IBS HK) - Apr 2026
Immvira is a clinical-stage biotechnology company with a dual-platform approach, developing both oncolytic immunotherapies and engineered...
143 Views
Pre-IPO Immvira Bioscience - The Pipeline, the Concerns and the Valuation
ImmVira faces challenges in commercializing pipelines due to high production costs and market competition, with valuation potentially ranging from...
512 Views